Magalys Vitiello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Magalys Vitiello has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Francisco A. Kerdel
Director of Inpatient Dermatology, University of Miami Hospital; Professor of Dermatology and Vice Chairman, Florida International University, Miami, FL
3 shared publications Adriana Abuchar
Florida Academic Dermatology Center, University of Miami Hospital, Miami, FL 33136, USA
2 shared publicationsAnnika Grant
2 shared publicationsLuis Dehesa
2 shared publicationsCarlos Ricotti
1 shared publication- Clara Milikowski
Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
1 shared publication
Latest Publications
- 1 August 2012
- Vol. 11 (8) , 950-4
Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis.
Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch therapy is used. The re-treatment with etanercept as part of the rotational therapy could be considered as another safe and efficient therapeutic approach. To evaluate the efficacy of the re-treatment with etanercept in patients with a history of etanercept use with good response and secondary loss of efficacy. This is an open label prospective study involving 20 patients with moderate to severe plaque psoriasis, who had been initially treated with etanercept and were re-treated after a variable interval with 50 mg BIW for 12 weeks. At week 12 of etanercept re-treatment, 13 of 20 patients (65%) achieved a PGA score of 2 or less and 40% (8 of 20), achieved a PGA score of 0 to 1. Etanercept was well tolerated and no serious adverse events were reported. Our study involved a small number of patients. Failure of etanercept was establish by patient's history. However we were able to correlate such failure from our medical records in 17 patients. Re-treatment with etanercept, after secondary loss of efficacy should be considered in patients with psoriasis if satisfactory therapy cannot be achieved with other therapeutic regimens.
- 1 August 2012
- Vol. 11 (8) , 950-4
Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis.
Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch therapy is used. The re-treatment with etanercept as part of the rotational therapy could be considered as another safe and efficient therapeutic approach. To evaluate the efficacy of the re-treatment with etanercept in patients with a history of etanercept use with good response and secondary loss of efficacy. This is an open label prospective study involving 20 patients with moderate to severe plaque psoriasis, who had been initially treated with etanercept and were re-treated after a variable interval with 50 mg BIW for 12 weeks. At week 12 of etanercept re-treatment, 13 of 20 patients (65%) achieved a PGA score of 2 or less and 40% (8 of 20), achieved a PGA score of 0 to 1. Etanercept was well tolerated and no serious adverse events were reported. Our study involved a small number of patients. Failure of etanercept was establish by patient's history. However we were able to correlate such failure from our medical records in 17 patients. Re-treatment with etanercept, after secondary loss of efficacy should be considered in patients with psoriasis if satisfactory therapy cannot be achieved with other therapeutic regimens.
- 1 July 2012
- Vol. 5 (7) , 33-43
An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.
Systemic sclerosis is a connective tissue disorder that affects multiple organs. Although the initial symptoms of the disease are vascular, skin involvement is almost universally present in patients with systemic sclerosis. The presence of Raynaud's phenomenon, progressive thickening of the skin, digital ulcers, and calcinosis all correlate proportionally with disease severity. Since no treatment is available to completely prevent the natural course of the disease, emphasis is often placed on managing symptoms and complications. In this review, the authors focus on the management of each one of the skin manifestations seen in systemic sclerosis, as the dermatologist may facilitate the early recognition and treatment of these complications.
- 1 July 2012
- Vol. 5 (7) , 33-43
An Update on the Treatment of the Cutaneous Manifestations of Systemic Sclerosis: The Dermatologist's Point of View.
Systemic sclerosis is a connective tissue disorder that affects multiple organs. Although the initial symptoms of the disease are vascular, skin involvement is almost universally present in patients with systemic sclerosis. The presence of Raynaud's phenomenon, progressive thickening of the skin, digital ulcers, and calcinosis all correlate proportionally with disease severity. Since no treatment is available to completely prevent the natural course of the disease, emphasis is often placed on managing symptoms and complications. In this review, the authors focus on the management of each one of the skin manifestations seen in systemic sclerosis, as the dermatologist may facilitate the early recognition and treatment of these complications.
- 19 August 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (9) , 1132-1134
Cutaneous sarcoid mimicking tinea imbricata
- 19 August 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (9) , 1132-1134
Cutaneous sarcoid mimicking tinea imbricata
- 22 July 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (8) , 1030-1032
An unusual case of cutaneous hyaline-vascular castleman’s disease with multicentric involvement and systemic symptoms
- 22 July 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (8) , 1030-1032
An unusual case of cutaneous hyaline-vascular castleman’s disease with multicentric involvement and systemic symptoms
- 1 April 2011
- Vol. 10 (4) , 418-21
Fatal cutaneous Strongyloidiasis as a side effect of Pemphigus foliaceus treatment with mycophenolate mofetil.
Strongyloidiasis is caused by the roundworm Strongyloides stercoralis (S. stercoralis). It is uncommon in the Unites States, and most cases are brought by travelers who have visited or lived in South America or Africa. Individuals with an intact immune system may experience mild gastrointestinal symptoms or none at all. In contrast, those with a compromised immune system may develop a rapidly fatal infection, commonly referred to as hyperinfection syndrome or disseminated Strongyloidiasis. We present a 66-year-old inmunocompromised male with Pemphigus Foliaceus who was admitted to the intensive care unit in critical condition and in whom a skin biopsy prove to be the main tool in the diagnosis of Strongyloidiasis.
- 1 April 2011
- Vol. 10 (4) , 418-21
Fatal cutaneous Strongyloidiasis as a side effect of Pemphigus foliaceus treatment with mycophenolate mofetil.
Strongyloidiasis is caused by the roundworm Strongyloides stercoralis (S. stercoralis). It is uncommon in the Unites States, and most cases are brought by travelers who have visited or lived in South America or Africa. Individuals with an intact immune system may experience mild gastrointestinal symptoms or none at all. In contrast, those with a compromised immune system may develop a rapidly fatal infection, commonly referred to as hyperinfection syndrome or disseminated Strongyloidiasis. We present a 66-year-old inmunocompromised male with Pemphigus Foliaceus who was admitted to the intensive care unit in critical condition and in whom a skin biopsy prove to be the main tool in the diagnosis of Strongyloidiasis.
- 18 March 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (4) , 478-482
Ustekinumab: when everything else fails?
- 18 March 2011
- Published by Wiley in International Journal of Dermatology
- Vol. 50 (4) , 478-482
Ustekinumab: when everything else fails?